OR3A1 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of OR3A1, a member of the olfactory receptor (OR) family of G-protein-coupled receptors (GPCRs). Olfactory receptors such as OR3A1 play a crucial role in detecting odorant molecules in the nasal epithelium, initiating a signal transduction pathway that leads to the perception of smell. When an odorant binds to OR3A1, it activates a G-protein, which in turn triggers a cascade of intracellular events, leading to changes in cellular signaling and the transmission of signals to the olfactory bulb in the brain. Beyond its role in olfaction, OR3A1, like many other olfactory receptors, is believed to be expressed in other tissues, where it might participate in various physiological processes not directly related to sensory perception.
The study of OR3A1 inhibitors helps researchers understand the specific functions of OR3A1 within both olfactory and non-olfactory contexts. By inhibiting OR3A1, scientists can explore the effects on signal transduction pathways linked to olfaction, providing insight into the molecular mechanisms underlying odor detection and interpretation. Additionally, given the potential presence of OR3A1 in non-olfactory tissues, these inhibitors serve as valuable tools for investigating the broader roles of OR3A1 in cellular communication and metabolism. Inhibiting OR3A1 allows researchers to dissect the complex interactions between olfactory receptors and other cellular signaling pathways, leading to a more comprehensive understanding of how GPCRs like OR3A1 regulate diverse biological processes. This contributes to the broader study of olfactory receptors as multifunctional proteins that may play important roles beyond their traditional function in the sense of smell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
Allosteric inhibitor that can modify GPCR conformation and inhibit receptor signaling. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
β-adrenergic receptor antagonist that can alter GPCR-mediated signaling pathways. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Selective antagonist of α2-adrenergic receptors that can inhibit related GPCR function. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Angiotensin II receptor antagonist that can modulate GPCR activity related to angiotensin signaling. | ||||||
Clozapine | 5786-21-0 | sc-200402 sc-200402A sc-200402B sc-200402C | 50 mg 500 mg 5 g 10 g | $69.00 $364.00 $2500.00 $4100.00 | 11 | |
Dopamine antagonist that can inhibit GPCR-related dopamine signaling pathways. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $82.00 $333.00 | 1 | |
Selective 5-HT3 receptor antagonist that can inhibit serotonin signaling through GPCRs. | ||||||
Naloxone | 465-65-6 | sc-477809 | 200 mg | $306.00 | 5 | |
Opioid receptor antagonist that can block opioid signaling through GPCRs. | ||||||
SCH 23390 | 125941-87-9 | sc-200408 sc-200408A | 5 mg 25 mg | $179.00 $733.00 | 2 | |
Dopamine D1 receptor antagonist that can alter signaling pathways involving related GPCRs. | ||||||